BerGenBio ASA (BRRGF)
USD 2.5
(0.0%)
USD 2.5
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.79 Million | -29.08 Million | -34 Million | -26.94 Million | -20.95 Million | -21.56 Million |
| Net Income | -18.69 Million | -30.8 Million | -35.03 Million | -30.01 Million | -22.67 Million | -22.14 Million |
| Depreciation & Amortization | 21.89 Thousand | 90.02 Thousand | 148.59 Thousand | 84.79 Thousand | 89.33 Thousand | 23.55 Thousand |
| Deferred income taxes | - | -2.6 Million | -6.83 Million | -5.99 Million | - | - |
| Stock-based compensation | 308.57 Thousand | 3.46 Million | 7.11 Million | 7.41 Million | 437.65 Thousand | - |
| Change in working capital | -3.28 Million | 1.03 Million | 577.61 Thousand | 1.58 Million | 1.49 Million | 166.99 Thousand |
| Other non-cash items | 3.47 Million | -268.63 Thousand | 30.01 Thousand | -7474.93 | -1.18 Million | 271.73 Thousand |
| Investing Cash Flow | 3.05 Million | 30.48 Thousand | 3.13 Million | -7825.32 | 251.29 Thousand | -26.33 Thousand |
| Investments in PPE | - | - | - | -7825.32 | - | -26.33 Thousand |
| Acquisitions | - | 30.48 Thousand | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 300.7 Thousand | 331.55 Thousand | 355.17 Thousand | 1000.00 | 251.29 Thousand | - |
| Financing Cash Flow | 22.07 Million | 296.06 Thousand | 1.81 Million | 81.69 Million | 8.79 Million | 20.44 Million |
| Debt repayment | -18.99 Thousand | -31.33 Thousand | -64.11 Thousand | -68.21 Thousand | -67.55 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 22.09 Million | 327.36 Thousand | 1.87 Million | 81.76 Million | 8.86 Million | 20.44 Million |
| Other Financing Activities | 22.15 Million | -31.29 Thousand | -63.87 Thousand | -68.32 Thousand | -67.48 Thousand | - |
| Accounts receivables | -159.23 Thousand | -352.95 Thousand | 207.26 Thousand | 185.7 Thousand | 229.08 Thousand | -508.24 Thousand |
| Accounts payables | -3.12 Million | 1.39 Million | 370.35 Thousand | 1.39 Million | 1.26 Million | 675.23 Thousand |
| Inventory | - | - | - | - | 1.00 | - |
| Other working capital | -31.76 Million | - | - | - | - | - |
| Cash at beginning of period | 15.37 Million | 49.45 Million | 84.28 Million | 28.85 Million | 41.61 Million | 45.27 Million |
| Cash at end of period | 15.35 Million | 15.37 Million | 49.45 Million | 84.28 Million | 28.85 Million | 41.61 Million |
| Capital Expenditure | - | - | - | -7825.32 | - | -26.33 Thousand |
| Effect of forex changes on cash | 2.78 Million | -3.76 Million | -779 Thousand | -710 Thousand | 37.81 Thousand | - |
| Net cash flow / Change in cash | -17.83 Thousand | -34.07 Million | -34.83 Million | 55.42 Million | -12.76 Million | -3.65 Million |
| Free Cash Flow | -21.79 Million | -29.08 Million | -34 Million | -26.94 Million | -20.95 Million | -21.58 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -4.65 Million | -3.33 Million | -18.69 Million | -4.08 Million | -2.6 Million | -4.54 Million |
| Depreciation & Amortization | 9825.90 | 9702.00 | 21.89 Thousand | 9915.68 | 10.18 Thousand | 651.42 |
| Deferred income taxes | - | - | - | - | -3.63 Million | -1.75 Million |
| Stock-based compensation | 166.44 Thousand | 1.69 Million | 3.13 Million | 538 Thousand | 829 Thousand | 198 Thousand |
| Change in working capital | 77.2 Thousand | -466.15 Thousand | -3.28 Million | 2.03 Million | -2.78 Million | -1.55 Million |
| Other non-cash items | 142.61 Thousand | 343.26 Thousand | 3.47 Million | -1.88 Million | 2.18 Million | 1.77 Million |
| Investing Cash Flow | -93.58 | 15.43 Thousand | 3.05 Million | 2.69 Million | 1.22 Million | 70 Thousand |
| Investments in PPE | 4.36 Million | - | - | - | - | - |
| Acquisitions | - | 15.43 Thousand | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 1779.68 | 19.45 Thousand | 300.7 Thousand | 265.46 Thousand | - | 6521.68 |
| Financing Cash Flow | 12.15 Million | -9424.80 | 22.07 Million | 743.47 Thousand | -8968.32 | 20.23 Million |
| Debt repayment | -9741.41 | -9405.13 | -18.99 Thousand | -9547.69 | -8974.00 | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 12.15 Million | - | 22.09 Million | 753 Thousand | - | 20.23 Million |
| Other Financing Activities | 12.17 Million | - | 22.15 Million | 754.95 Thousand | - | 20.25 Million |
| Accounts receivables | -34.71 Thousand | -41.02 Thousand | -159.23 Thousand | 65.67 Thousand | -346.96 Thousand | -172.06 Thousand |
| Accounts payables | 111.92 Thousand | -425.13 Thousand | -3.12 Million | 1.97 Million | -2.43 Million | -1.38 Million |
| Inventory | - | - | - | - | - | -1.00 |
| Other working capital | 1.19 Million | - | - | - | -1.00 | - |
| Cash at beginning of period | 10.84 Million | 15.35 Million | 15.37 Million | 15.81 Million | 21.02 Million | 6.96 Million |
| Cash at end of period | 18.72 Million | 10.84 Million | 15.35 Million | 15.35 Million | 15.81 Million | 21.02 Million |
| Capital Expenditure | 4.36 Million | - | - | - | - | - |
| Effect of forex changes on cash | -416 Thousand | 3.45 Million | 2.78 Million | -1.05 Million | -1.22 Million | -1.19 Million |
| Net cash flow / Change in cash | 7.88 Million | -4.51 Million | -17.83 Thousand | -460.68 Thousand | -5.21 Million | 14.06 Million |
| Free Cash Flow | - | -3.93 Million | -21.79 Million | -1.9 Million | -6 Million | -5.88 Million |
NTQ
DBX
6804
JBTC
ACST
376300